Hostname: page-component-586b7cd67f-tf8b9 Total loading time: 0 Render date: 2024-11-28T10:15:50.594Z Has data issue: false hasContentIssue false
  • English
  • Français

The interaction of subjective experience and attitudes towards specific antipsychotic-related adverse effects in schizophrenia patients

Published online by Cambridge University Press:  15 April 2020

T. Fischel ,
A. Krivoy ,
M. Kotlarov ,
Z. Zemishlany ,
O. Loebstein ,
H. Jacoby  and
A. Weizman
T. Fischel
Affiliation:
Geha Mental Health Center, 1, Helsinki Street, P.O. Box 103, 49100Petach-Tikva, Israel Sackler's Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel
A. Krivoy*
Affiliation:
Geha Mental Health Center, 1, Helsinki Street, P.O. Box 103, 49100Petach-Tikva, Israel Sackler's Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel
M. Kotlarov
Affiliation:
Sackler's Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel
Z. Zemishlany
Affiliation:
Geha Mental Health Center, 1, Helsinki Street, P.O. Box 103, 49100Petach-Tikva, Israel Sackler's Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel
O. Loebstein
Affiliation:
Geha Mental Health Center, 1, Helsinki Street, P.O. Box 103, 49100Petach-Tikva, Israel Sackler's Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel
H. Jacoby
Affiliation:
Geha Mental Health Center, 1, Helsinki Street, P.O. Box 103, 49100Petach-Tikva, Israel
A. Weizman
Affiliation:
Geha Mental Health Center, 1, Helsinki Street, P.O. Box 103, 49100Petach-Tikva, Israel Sackler's Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel Felsenstein Medical Research Center, Petach-Tikva, Israel
*
*Corresponding author. Tel.: +972 3 925 8230; fax: +972 3 925 8235. E-mail address:[email protected] (A. Krivoy).
Get access

Abstract

Background:

Discontinuation of antipsychotic drugs in schizophrenia patients is a major concern, since it results in relapse and re-hospitalizations. Non-adherence is strongly associated with negative-subjective response to antipsychotics, which is composed of the subjective experience of negative drug effects and attitude towards the treatment.

Objective:

To investigate the elements of subjective experience and subjective attitude towards specific drug-related adverse effects, leading to a generally negative-subjective attitude towards antipsychotics.

Methods:

Schizophrenia inpatients (n = 84) were administered a questionnaire measuring attitude and experience on eight subscales: weight gain, sedation, sexual anhedonia, extra-pyramidal syndrome, affective flattening, excessive sleep, diminished sociability and metabolic syndrome. DAI-30 was used to measure attitude towards drugs, and PANSS to assess psychopathology.

Results:

Weak correlation was found between subjective experience and attitude on most of the subscales. The only strong, albeit inverse, correlation between experience and attitude that was found was with regard to affective flattening, experienced by 37% of the sample, and it also predicted negative drug attitude as measured by the DAI-30, RR: 1.87 (95% CI: 1.06–3.3, df = 1, χ2 = 4.525, P < 0.05).

Conclusion:

Negative attitude towards most adverse drug effects did not correlate with personal experience. Drug-related affective flattening should be evaluated routinely, since experiencing it may predict negative attitude towards drugs, potentially leading to poor compliance and relapse.

Keywords

SchizophreniaAntipsychotic drugsSubjective attitudeSubjective experienceAffective flattening
Type
Original article
Information
European Psychiatry , Volume 28 , Issue 6 , August 2013 , pp. 340 - 343
Copyright
Copyright © European Psychiatric Association

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Footnotes

1

Both authors contributed equally to this manuscript.

References

Awad, AGHogan, TPSubjective response to neuroleptics and the quality of life: implications for treatment outcome. Acta Psychiatr Scand Suppl 1994;380:27–32.CrossRefGoogle ScholarPubMed
Awad, AGVoruganti, LNHeslegrave, RJHogan, TPAssessment of the patient's subjective experience in acute neuroleptic treatment: implications for compliance and outcome. Int Clin Psychopharmacol 1996;11(Suppl. 2):55–59.CrossRefGoogle ScholarPubMed
Buchanan, RWKreyenbuhl, JKelly, DLNoel, JMBoggs, DLFischer, BA, et al.The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull 2010;36(1):71–93.CrossRefGoogle ScholarPubMed
Gaebel, WRiesbeck, Mvon, WMBurns, TDerks, EMKahn, RS, et al.Drug attitude as predictor for effectiveness in first-episode schizophrenia: results of an open randomized trial (EUFEST). Eur Neuropsychopharmacol 2010;20(5):310–316.CrossRefGoogle Scholar
Hellewell, JSPatients’ subjective experiences of antipsychotics: clinical relevance. CNS Drugs 2002;16(7):457–471.CrossRefGoogle ScholarPubMed
Hofer, AKemmler, GEder, UHoneder, MHummer, MFleischhacker, WWAttitudes toward antipsychotics among outpatient clinic attendees with schizophrenia. J Clin Psychiatry 2002;63(1):49–53.CrossRefGoogle ScholarPubMed
Hofer, ARettenbacher, MAEdlinger, MKemmler, GWidschwendter, CGFleischhacker, WWSubjective response and attitudes toward antipsychotic drug therapy during the initial treatment period: a prospective follow-up study in patients with schizophrenia. Acta Psychiatr Scand 2007;116(5):354–361.CrossRefGoogle ScholarPubMed
Hogan, TPAwad, AGEastwood, RA self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychol Med 1983;13(1):177–183.CrossRefGoogle ScholarPubMed
Hogan, TPAwad, AGEastwood, MREarly subjective response and prediction of outcome to neuroleptic drug therapy in schizophrenia. Can J Psychiatry 1985;30(4):246–248.CrossRefGoogle Scholar
Jones, PBBarnes, TRDavies, LDunn, GLloyd, HHayhurst, KP, et al.Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry 2006;63(10):1079–1087.CrossRefGoogle Scholar
Kahn, RSFleischhacker, WWBoter, HDavidson, MVergouwe, YKeet, IP, et al.Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 2008;371(9618):1085–1097.CrossRefGoogle ScholarPubMed
Lacro, JPDunn, LBDolder, CRLeckband, SGJeste, DVPrevalence of and risk factors for medication non-adherence in patients with schizophrenia: a comprehensive review of recent literature. J Clin Psychiatry 2002;63(10):892–909.CrossRefGoogle ScholarPubMed
Lieberman, JAStroup, TSMcEvoy, JPSwartz, MSRosenheck, RAPerkins, DO, et al.Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353(12):1209–1223.CrossRefGoogle ScholarPubMed
Moncrieff, JCohen, DMason, JPThe subjective experience of taking antipsychotic medication: a content analysis of Internet data. Acta Psychiatr Scand 2009;120(2):102–111.CrossRefGoogle ScholarPubMed
Naber, DSubjective effects of antipsychotic drugs and their relevance for compliance and remission. Epidemiol Psichiatr Soc 2008;17(3):174–176.CrossRefGoogle ScholarPubMed
Novick, DHaro, JMSuarez, DPerez, VDittmann, RWHaddad, PMPredictors and clinical consequences of non-adherence with antipsychotic medication in the outpatient treatment of schizophrenia. Psychiatry Res 2010;176(2–3):109–113.CrossRefGoogle ScholarPubMed
Velligan, DIWeiden, PJSajatovic, MScott, JCarpenter, DRoss, R, et al.Strategies for addressing adherence problems in patients with serious and persistent mental illness: recommendations from the expert consensus guidelines. J Psychiatr Pract 2010;16(5):306–324.CrossRefGoogle ScholarPubMed
Wolters, HAKnegtering, RWiersma, Dvan den Bosch, RJEvaluation of the subjects’ response to antipsychotics questionnaire. Int Clin Psychopharmacol 2006;21(1):63–69.CrossRefGoogle ScholarPubMed
Wolters, HAKnegtering, Hvan den Bosch, RJWiersma, DEffects and side effects of antipsychotic treatment in schizophrenia: pros and cons of available self-rating scales. Schizophr Res 2009;112(1-3):114–118.CrossRefGoogle ScholarPubMed
Submit a response

Comments

No Comments have been published for this article.